Acute Myeloid Leukemia (AML)
203
37
48
75
Key Insights
Highlights
Success Rate
64% trial completion
Published Results
42 trials with published results (21%)
Research Maturity
75 completed trials (37% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 64/100
20.7%
42 terminated out of 203 trials
64.1%
-22.4% vs benchmark
12%
24 trials in Phase 3/4
56%
42 of 75 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 75 completed trials
Clinical Trials (203)
A Modified Dose of Rabbit Anti-thymocyte Globulin (rATG) in Children and Adults Receiving Treatment to Help Prepare Their Bodies for a Bone Marrow Transplant
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
Thiotepa-based Conditioning Regimen With De-escalated Post-graft Cyclophosphamide for Allogeneic Stem Cell Transplantation in Hematologic Malignancies
Venetoclax in Combination With 5 Days Azacitidine in Untreated AML Patients, Not Eligible for Standard Induction Therapy
ADCT-301 in Patients With R/R AML, MDS, or MDS/MPN
Ivosidenib as Post-HSCT Maintenance for AML
Monitoring, Detoxifying, and Rebalancing Metals During Acute Myeloid Leukemia (AML) Therapy, a Phase 2 Randomized Study
Clinical AML Registry and Biomaterial Database of the Study Alliance Leukemia (SAL)
Leukemia Stem Cell-based Assay to Predict Relapse and Survival in Patients With Acute Myeloid Leukemia
TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT
Proton-Based Total Marrow Irradiation for Allogeneic Transplantation in High-Risk AML/MDS
VAH vs VA in Newly Diagnosed Elderly AML
TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
A Study of Oral Venetoclax Tablets and Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy
Exploratory Study of Venetoclax, Homoharringtonine, Azacitidine Plus G-CSF for Newly Diagnosed AML (VHAG)
Efficacy and Safety of Lisafotoclax Plus Decitabine and Homoharringtonine in Venetoclax/Azacitidine Pretreated AML Patients
Digital PCR of CHIP and MR for MRD Monitoring After Allo-HSCT in AML
A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)
MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib